Histogenics Completes 50% Enrollment in NeoCart Phase III Trial

Histogenics has enrolled 123 (>50%) of the 245 patients required to complete enrollment in its ongoing NeoCart® Phase III clinical trial.  This trial is being conducted under a Special Protocol Assessment with FDA.

Company leadership attributes its progress to enrollment-enhancing strategies implemented in 2015, as well as changes by FDA in...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us